Common Equity: The sum of all common equity items.
NewAmsterdam Pharma Company N.V. (NAMS) had Common Equity of $683.43M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.03M |
|
$-74.92M |
|
-- |
|
$0.03M |
|
$66.01M |
|
$-65.98M |
|
$-8.94M |
|
$-74.92M |
|
$-74.92M |
|
$-74.92M |
|
$-74.92M |
|
$-74.92M |
|
$-74.92M |
|
$-65.98M |
|
$-65.92M |
|
118.42M |
|
118.42M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$675.70M |
|
$0.38M |
|
$93.58M |
|
$769.28M |
|
$85.79M |
|
-- |
|
$0.07M |
|
$85.85M |
|
|
Common Equity |
$683.43M |
$683.02M |
|
$683.43M |
|
114.40M |
|
| Cash Flow Statement Financials | |
$-147.78M |
|
$-174.92M |
|
$29.52M |
|
$771.74M |
|
$491.32M |
|
$-280.42M |
|
$59.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-206185.60% |
|
-206185.50% |
|
-- |
|
-234132.20% |
|
-234132.20% |
|
$-148.03M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-10.96% |
|
-10.97% |
|
-9.74% |
|
-10.96% |
|
$5.97 |
|
$-1.25 |
|
$-1.25 |
|